nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—HTR2C—Sorafenib—thyroid cancer	0.182	0.542	CbGbCtD
Duloxetine—CYP1A2—Sorafenib—thyroid cancer	0.0664	0.197	CbGbCtD
Duloxetine—CYP2D6—Sorafenib—thyroid cancer	0.0547	0.162	CbGbCtD
Duloxetine—CYP2D6—Doxorubicin—thyroid cancer	0.0332	0.0986	CbGbCtD
Duloxetine—Dehydration—Epirubicin—thyroid cancer	0.000584	0.000979	CcSEcCtD
Duloxetine—Hyponatraemia—Doxorubicin—thyroid cancer	0.000584	0.000978	CcSEcCtD
Duloxetine—Pain in extremity—Doxorubicin—thyroid cancer	0.000581	0.000974	CcSEcCtD
Duloxetine—Osteoarthritis—Doxorubicin—thyroid cancer	0.000581	0.000974	CcSEcCtD
Duloxetine—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.000581	0.000974	CcSEcCtD
Duloxetine—Diplopia—Doxorubicin—thyroid cancer	0.000581	0.000974	CcSEcCtD
Duloxetine—Liver function test abnormal—Epirubicin—thyroid cancer	0.00058	0.000972	CcSEcCtD
Duloxetine—Orthostatic hypotension—Epirubicin—thyroid cancer	0.000574	0.000962	CcSEcCtD
Duloxetine—Abdominal pain upper—Epirubicin—thyroid cancer	0.000574	0.000962	CcSEcCtD
Duloxetine—Affect lability—Doxorubicin—thyroid cancer	0.000572	0.000959	CcSEcCtD
Duloxetine—Migraine—Doxorubicin—thyroid cancer	0.000572	0.000959	CcSEcCtD
Duloxetine—Diarrhoea—Sorafenib—thyroid cancer	0.000572	0.000958	CcSEcCtD
Duloxetine—Breast disorder—Epirubicin—thyroid cancer	0.000568	0.000952	CcSEcCtD
Duloxetine—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000566	0.000948	CcSEcCtD
Duloxetine—Nasopharyngitis—Epirubicin—thyroid cancer	0.000562	0.000942	CcSEcCtD
Duloxetine—Face oedema—Doxorubicin—thyroid cancer	0.000561	0.000941	CcSEcCtD
Duloxetine—Gastritis—Epirubicin—thyroid cancer	0.000556	0.000932	CcSEcCtD
Duloxetine—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.000554	0.000929	CcSEcCtD
Duloxetine—Muscular weakness—Epirubicin—thyroid cancer	0.000554	0.000929	CcSEcCtD
Duloxetine—Dizziness—Sorafenib—thyroid cancer	0.000553	0.000926	CcSEcCtD
Duloxetine—Mood swings—Doxorubicin—thyroid cancer	0.000551	0.000923	CcSEcCtD
Duloxetine—Ataxia—Doxorubicin—thyroid cancer	0.000547	0.000916	CcSEcCtD
Duloxetine—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000545	0.000913	CcSEcCtD
Duloxetine—Influenza—Epirubicin—thyroid cancer	0.000543	0.00091	CcSEcCtD
Duloxetine—Dysphagia—Epirubicin—thyroid cancer	0.000543	0.00091	CcSEcCtD
Duloxetine—Dehydration—Doxorubicin—thyroid cancer	0.000541	0.000906	CcSEcCtD
Duloxetine—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000537	0.0009	CcSEcCtD
Duloxetine—Pancreatitis—Epirubicin—thyroid cancer	0.000532	0.000892	CcSEcCtD
Duloxetine—Vomiting—Sorafenib—thyroid cancer	0.000531	0.000891	CcSEcCtD
Duloxetine—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000531	0.00089	CcSEcCtD
Duloxetine—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000531	0.00089	CcSEcCtD
Duloxetine—Rash—Sorafenib—thyroid cancer	0.000527	0.000883	CcSEcCtD
Duloxetine—Dermatitis—Sorafenib—thyroid cancer	0.000526	0.000882	CcSEcCtD
Duloxetine—Breast disorder—Doxorubicin—thyroid cancer	0.000525	0.000881	CcSEcCtD
Duloxetine—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000524	0.000878	CcSEcCtD
Duloxetine—Headache—Sorafenib—thyroid cancer	0.000524	0.000877	CcSEcCtD
Duloxetine—Nasopharyngitis—Doxorubicin—thyroid cancer	0.00052	0.000871	CcSEcCtD
Duloxetine—Gastritis—Doxorubicin—thyroid cancer	0.000515	0.000862	CcSEcCtD
Duloxetine—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000513	0.000859	CcSEcCtD
Duloxetine—Muscular weakness—Doxorubicin—thyroid cancer	0.000513	0.000859	CcSEcCtD
Duloxetine—Dysuria—Epirubicin—thyroid cancer	0.000508	0.000851	CcSEcCtD
Duloxetine—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000505	0.000846	CcSEcCtD
Duloxetine—Influenza—Doxorubicin—thyroid cancer	0.000503	0.000842	CcSEcCtD
Duloxetine—Dysphagia—Doxorubicin—thyroid cancer	0.000503	0.000842	CcSEcCtD
Duloxetine—Pollakiuria—Epirubicin—thyroid cancer	0.000502	0.000841	CcSEcCtD
Duloxetine—Nausea—Sorafenib—thyroid cancer	0.000496	0.000832	CcSEcCtD
Duloxetine—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000496	0.000831	CcSEcCtD
Duloxetine—Weight increased—Epirubicin—thyroid cancer	0.000494	0.000828	CcSEcCtD
Duloxetine—Pancreatitis—Doxorubicin—thyroid cancer	0.000493	0.000826	CcSEcCtD
Duloxetine—Weight decreased—Epirubicin—thyroid cancer	0.000491	0.000824	CcSEcCtD
Duloxetine—Hyperglycaemia—Epirubicin—thyroid cancer	0.00049	0.000821	CcSEcCtD
Duloxetine—Infestation NOS—Epirubicin—thyroid cancer	0.000484	0.000812	CcSEcCtD
Duloxetine—Infestation—Epirubicin—thyroid cancer	0.000484	0.000812	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.00048	0.000805	CcSEcCtD
Duloxetine—Renal failure—Epirubicin—thyroid cancer	0.000476	0.000798	CcSEcCtD
Duloxetine—Stomatitis—Epirubicin—thyroid cancer	0.000472	0.000791	CcSEcCtD
Duloxetine—Jaundice—Epirubicin—thyroid cancer	0.000472	0.000791	CcSEcCtD
Duloxetine—Urinary tract infection—Epirubicin—thyroid cancer	0.000471	0.000789	CcSEcCtD
Duloxetine—Conjunctivitis—Epirubicin—thyroid cancer	0.000471	0.000789	CcSEcCtD
Duloxetine—Dysuria—Doxorubicin—thyroid cancer	0.00047	0.000788	CcSEcCtD
Duloxetine—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000467	0.000783	CcSEcCtD
Duloxetine—Pollakiuria—Doxorubicin—thyroid cancer	0.000464	0.000778	CcSEcCtD
Duloxetine—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000459	0.000769	CcSEcCtD
Duloxetine—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000458	0.000768	CcSEcCtD
Duloxetine—Weight increased—Doxorubicin—thyroid cancer	0.000457	0.000766	CcSEcCtD
Duloxetine—Epistaxis—Epirubicin—thyroid cancer	0.000457	0.000766	CcSEcCtD
Duloxetine—NPY1R—saliva-secreting gland—thyroid cancer	0.000456	0.214	CbGeAlD
Duloxetine—Weight decreased—Doxorubicin—thyroid cancer	0.000455	0.000762	CcSEcCtD
Duloxetine—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000453	0.00076	CcSEcCtD
Duloxetine—Infestation NOS—Doxorubicin—thyroid cancer	0.000448	0.000751	CcSEcCtD
Duloxetine—Infestation—Doxorubicin—thyroid cancer	0.000448	0.000751	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000444	0.000745	CcSEcCtD
Duloxetine—Renal failure—Doxorubicin—thyroid cancer	0.00044	0.000738	CcSEcCtD
Duloxetine—Haemoglobin—Epirubicin—thyroid cancer	0.000437	0.000732	CcSEcCtD
Duloxetine—Stomatitis—Doxorubicin—thyroid cancer	0.000437	0.000732	CcSEcCtD
Duloxetine—Jaundice—Doxorubicin—thyroid cancer	0.000437	0.000732	CcSEcCtD
Duloxetine—Conjunctivitis—Doxorubicin—thyroid cancer	0.000436	0.00073	CcSEcCtD
Duloxetine—Urinary tract infection—Doxorubicin—thyroid cancer	0.000436	0.00073	CcSEcCtD
Duloxetine—Haemorrhage—Epirubicin—thyroid cancer	0.000435	0.000729	CcSEcCtD
Duloxetine—Hepatitis—Epirubicin—thyroid cancer	0.000435	0.000729	CcSEcCtD
Duloxetine—Hypoaesthesia—Epirubicin—thyroid cancer	0.000433	0.000725	CcSEcCtD
Duloxetine—Pharyngitis—Epirubicin—thyroid cancer	0.000431	0.000723	CcSEcCtD
Duloxetine—Urinary tract disorder—Epirubicin—thyroid cancer	0.000429	0.00072	CcSEcCtD
Duloxetine—Oedema peripheral—Epirubicin—thyroid cancer	0.000428	0.000718	CcSEcCtD
Duloxetine—Connective tissue disorder—Epirubicin—thyroid cancer	0.000427	0.000716	CcSEcCtD
Duloxetine—Urethral disorder—Epirubicin—thyroid cancer	0.000426	0.000714	CcSEcCtD
Duloxetine—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000424	0.00071	CcSEcCtD
Duloxetine—Epistaxis—Doxorubicin—thyroid cancer	0.000423	0.000708	CcSEcCtD
Duloxetine—Visual impairment—Epirubicin—thyroid cancer	0.000419	0.000702	CcSEcCtD
Duloxetine—Erythema multiforme—Epirubicin—thyroid cancer	0.000411	0.000689	CcSEcCtD
Duloxetine—Eye disorder—Epirubicin—thyroid cancer	0.000406	0.000681	CcSEcCtD
Duloxetine—Tinnitus—Epirubicin—thyroid cancer	0.000405	0.000679	CcSEcCtD
Duloxetine—HTR2C—GPCR ligand binding—CALCB—thyroid cancer	0.000404	0.00627	CbGpPWpGaD
Duloxetine—Haemoglobin—Doxorubicin—thyroid cancer	0.000404	0.000678	CcSEcCtD
Duloxetine—Flushing—Epirubicin—thyroid cancer	0.000403	0.000676	CcSEcCtD
Duloxetine—Cardiac disorder—Epirubicin—thyroid cancer	0.000403	0.000676	CcSEcCtD
Duloxetine—HTR2A—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—KRAS—thyroid cancer	0.000403	0.00625	CbGpPWpGaD
Duloxetine—Haemorrhage—Doxorubicin—thyroid cancer	0.000402	0.000674	CcSEcCtD
Duloxetine—Hepatitis—Doxorubicin—thyroid cancer	0.000402	0.000674	CcSEcCtD
Duloxetine—Hypoaesthesia—Doxorubicin—thyroid cancer	0.0004	0.000671	CcSEcCtD
Duloxetine—Pharyngitis—Doxorubicin—thyroid cancer	0.000399	0.000669	CcSEcCtD
Duloxetine—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000397	0.000666	CcSEcCtD
Duloxetine—Oedema peripheral—Doxorubicin—thyroid cancer	0.000396	0.000664	CcSEcCtD
Duloxetine—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000395	0.000662	CcSEcCtD
Duloxetine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HRAS—thyroid cancer	0.000395	0.00612	CbGpPWpGaD
Duloxetine—Angiopathy—Epirubicin—thyroid cancer	0.000394	0.000661	CcSEcCtD
Duloxetine—Urethral disorder—Doxorubicin—thyroid cancer	0.000394	0.000661	CcSEcCtD
Duloxetine—Immune system disorder—Epirubicin—thyroid cancer	0.000393	0.000658	CcSEcCtD
Duloxetine—Mediastinal disorder—Epirubicin—thyroid cancer	0.000392	0.000657	CcSEcCtD
Duloxetine—Chills—Epirubicin—thyroid cancer	0.00039	0.000654	CcSEcCtD
Duloxetine—NPY1R—GPCR downstream signaling—TSHR—thyroid cancer	0.00039	0.00604	CbGpPWpGaD
Duloxetine—Arrhythmia—Epirubicin—thyroid cancer	0.000388	0.000651	CcSEcCtD
Duloxetine—Visual impairment—Doxorubicin—thyroid cancer	0.000388	0.00065	CcSEcCtD
Duloxetine—Alopecia—Epirubicin—thyroid cancer	0.000384	0.000644	CcSEcCtD
Duloxetine—Mental disorder—Epirubicin—thyroid cancer	0.000381	0.000638	CcSEcCtD
Duloxetine—Erythema multiforme—Doxorubicin—thyroid cancer	0.00038	0.000637	CcSEcCtD
Duloxetine—Malnutrition—Epirubicin—thyroid cancer	0.000378	0.000634	CcSEcCtD
Duloxetine—Erythema—Epirubicin—thyroid cancer	0.000378	0.000634	CcSEcCtD
Duloxetine—Eye disorder—Doxorubicin—thyroid cancer	0.000376	0.00063	CcSEcCtD
Duloxetine—Tinnitus—Doxorubicin—thyroid cancer	0.000375	0.000629	CcSEcCtD
Duloxetine—Flushing—Doxorubicin—thyroid cancer	0.000373	0.000626	CcSEcCtD
Duloxetine—Cardiac disorder—Doxorubicin—thyroid cancer	0.000373	0.000626	CcSEcCtD
Duloxetine—Flatulence—Epirubicin—thyroid cancer	0.000373	0.000625	CcSEcCtD
Duloxetine—SLC6A3—NRF2 pathway—SLC5A5—thyroid cancer	0.000372	0.00577	CbGpPWpGaD
Duloxetine—Tension—Epirubicin—thyroid cancer	0.000371	0.000622	CcSEcCtD
Duloxetine—Dysgeusia—Epirubicin—thyroid cancer	0.000371	0.000621	CcSEcCtD
Duloxetine—CYP1A2—Metapathway biotransformation—CHST14—thyroid cancer	0.000369	0.00572	CbGpPWpGaD
Duloxetine—Nervousness—Epirubicin—thyroid cancer	0.000368	0.000616	CcSEcCtD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.000367	0.00569	CbGpPWpGaD
Duloxetine—Back pain—Epirubicin—thyroid cancer	0.000366	0.000614	CcSEcCtD
Duloxetine—Angiopathy—Doxorubicin—thyroid cancer	0.000365	0.000612	CcSEcCtD
Duloxetine—Muscle spasms—Epirubicin—thyroid cancer	0.000364	0.00061	CcSEcCtD
Duloxetine—Immune system disorder—Doxorubicin—thyroid cancer	0.000363	0.000609	CcSEcCtD
Duloxetine—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000363	0.000608	CcSEcCtD
Duloxetine—Chills—Doxorubicin—thyroid cancer	0.000361	0.000605	CcSEcCtD
Duloxetine—Arrhythmia—Doxorubicin—thyroid cancer	0.000359	0.000602	CcSEcCtD
Duloxetine—Vision blurred—Epirubicin—thyroid cancer	0.000357	0.000598	CcSEcCtD
Duloxetine—Alopecia—Doxorubicin—thyroid cancer	0.000355	0.000596	CcSEcCtD
Duloxetine—SLC6A4—NRF2 pathway—NRG1—thyroid cancer	0.000355	0.00551	CbGpPWpGaD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000354	0.00549	CbGpPWpGaD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000354	0.00549	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—TSHR—thyroid cancer	0.000354	0.00548	CbGpPWpGaD
Duloxetine—SLC6A2—NRF2 pathway—RXRA—thyroid cancer	0.000353	0.00548	CbGpPWpGaD
Duloxetine—Mental disorder—Doxorubicin—thyroid cancer	0.000352	0.000591	CcSEcCtD
Duloxetine—HTR2A—GPCR ligand binding—CALCB—thyroid cancer	0.000351	0.00545	CbGpPWpGaD
Duloxetine—Ill-defined disorder—Epirubicin—thyroid cancer	0.000351	0.000588	CcSEcCtD
Duloxetine—Erythema—Doxorubicin—thyroid cancer	0.00035	0.000587	CcSEcCtD
Duloxetine—Malnutrition—Doxorubicin—thyroid cancer	0.00035	0.000587	CcSEcCtD
Duloxetine—Anaemia—Epirubicin—thyroid cancer	0.00035	0.000586	CcSEcCtD
Duloxetine—NPY1R—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000348	0.0054	CbGpPWpGaD
Duloxetine—Agitation—Epirubicin—thyroid cancer	0.000348	0.000583	CcSEcCtD
Duloxetine—Flatulence—Doxorubicin—thyroid cancer	0.000345	0.000578	CcSEcCtD
Duloxetine—Tension—Doxorubicin—thyroid cancer	0.000344	0.000576	CcSEcCtD
Duloxetine—Dysgeusia—Doxorubicin—thyroid cancer	0.000343	0.000575	CcSEcCtD
Duloxetine—HTR2A—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HRAS—thyroid cancer	0.000343	0.00531	CbGpPWpGaD
Duloxetine—Malaise—Epirubicin—thyroid cancer	0.000341	0.000572	CcSEcCtD
Duloxetine—Nervousness—Doxorubicin—thyroid cancer	0.00034	0.00057	CcSEcCtD
Duloxetine—Vertigo—Epirubicin—thyroid cancer	0.00034	0.00057	CcSEcCtD
Duloxetine—Syncope—Epirubicin—thyroid cancer	0.000339	0.000569	CcSEcCtD
Duloxetine—Leukopenia—Epirubicin—thyroid cancer	0.000339	0.000568	CcSEcCtD
Duloxetine—Back pain—Doxorubicin—thyroid cancer	0.000339	0.000568	CcSEcCtD
Duloxetine—Muscle spasms—Doxorubicin—thyroid cancer	0.000337	0.000564	CcSEcCtD
Duloxetine—Palpitations—Epirubicin—thyroid cancer	0.000334	0.00056	CcSEcCtD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000334	0.00518	CbGpPWpGaD
Duloxetine—Loss of consciousness—Epirubicin—thyroid cancer	0.000333	0.000557	CcSEcCtD
Duloxetine—Cough—Epirubicin—thyroid cancer	0.00033	0.000553	CcSEcCtD
Duloxetine—Vision blurred—Doxorubicin—thyroid cancer	0.00033	0.000553	CcSEcCtD
Duloxetine—Convulsion—Epirubicin—thyroid cancer	0.000328	0.00055	CcSEcCtD
Duloxetine—Hypertension—Epirubicin—thyroid cancer	0.000327	0.000548	CcSEcCtD
Duloxetine—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000325	0.000545	CcSEcCtD
Duloxetine—Anaemia—Doxorubicin—thyroid cancer	0.000324	0.000542	CcSEcCtD
Duloxetine—Chest pain—Epirubicin—thyroid cancer	0.000322	0.00054	CcSEcCtD
Duloxetine—Myalgia—Epirubicin—thyroid cancer	0.000322	0.00054	CcSEcCtD
Duloxetine—Arthralgia—Epirubicin—thyroid cancer	0.000322	0.00054	CcSEcCtD
Duloxetine—Agitation—Doxorubicin—thyroid cancer	0.000322	0.000539	CcSEcCtD
Duloxetine—Anxiety—Epirubicin—thyroid cancer	0.000321	0.000538	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00032	0.000536	CcSEcCtD
Duloxetine—Discomfort—Epirubicin—thyroid cancer	0.000318	0.000534	CcSEcCtD
Duloxetine—Malaise—Doxorubicin—thyroid cancer	0.000316	0.000529	CcSEcCtD
Duloxetine—Dry mouth—Epirubicin—thyroid cancer	0.000315	0.000528	CcSEcCtD
Duloxetine—Vertigo—Doxorubicin—thyroid cancer	0.000315	0.000527	CcSEcCtD
Duloxetine—Syncope—Doxorubicin—thyroid cancer	0.000314	0.000526	CcSEcCtD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000314	0.00486	CbGpPWpGaD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000314	0.00486	CbGpPWpGaD
Duloxetine—Leukopenia—Doxorubicin—thyroid cancer	0.000313	0.000525	CcSEcCtD
Duloxetine—SLC6A3—NRF2 pathway—RXRA—thyroid cancer	0.000313	0.00485	CbGpPWpGaD
Duloxetine—Confusional state—Epirubicin—thyroid cancer	0.000311	0.000522	CcSEcCtD
Duloxetine—HTR6—GPCR downstream signaling—CALCB—thyroid cancer	0.00031	0.00481	CbGpPWpGaD
Duloxetine—Palpitations—Doxorubicin—thyroid cancer	0.000309	0.000519	CcSEcCtD
Duloxetine—Anaphylactic shock—Epirubicin—thyroid cancer	0.000309	0.000518	CcSEcCtD
Duloxetine—Oedema—Epirubicin—thyroid cancer	0.000309	0.000518	CcSEcCtD
Duloxetine—Loss of consciousness—Doxorubicin—thyroid cancer	0.000308	0.000516	CcSEcCtD
Duloxetine—Infection—Epirubicin—thyroid cancer	0.000307	0.000514	CcSEcCtD
Duloxetine—Cough—Doxorubicin—thyroid cancer	0.000306	0.000512	CcSEcCtD
Duloxetine—SLC6A2—NRF2 pathway—NRG1—thyroid cancer	0.000305	0.00473	CbGpPWpGaD
Duloxetine—Shock—Epirubicin—thyroid cancer	0.000304	0.000509	CcSEcCtD
Duloxetine—Convulsion—Doxorubicin—thyroid cancer	0.000303	0.000508	CcSEcCtD
Duloxetine—NPY1R—GPCR downstream signaling—SST—thyroid cancer	0.000303	0.0047	CbGpPWpGaD
Duloxetine—Nervous system disorder—Epirubicin—thyroid cancer	0.000303	0.000508	CcSEcCtD
Duloxetine—Thrombocytopenia—Epirubicin—thyroid cancer	0.000302	0.000507	CcSEcCtD
Duloxetine—Hypertension—Doxorubicin—thyroid cancer	0.000302	0.000507	CcSEcCtD
Duloxetine—Tachycardia—Epirubicin—thyroid cancer	0.000301	0.000505	CcSEcCtD
Duloxetine—NPY1R—Signaling by GPCR—PTCH1—thyroid cancer	0.000301	0.00466	CbGpPWpGaD
Duloxetine—Skin disorder—Epirubicin—thyroid cancer	0.0003	0.000503	CcSEcCtD
Duloxetine—Hyperhidrosis—Epirubicin—thyroid cancer	0.000299	0.0005	CcSEcCtD
Duloxetine—CYP2D6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000299	0.00463	CbGpPWpGaD
Duloxetine—Myalgia—Doxorubicin—thyroid cancer	0.000298	0.0005	CcSEcCtD
Duloxetine—Arthralgia—Doxorubicin—thyroid cancer	0.000298	0.0005	CcSEcCtD
Duloxetine—Chest pain—Doxorubicin—thyroid cancer	0.000298	0.0005	CcSEcCtD
Duloxetine—Anxiety—Doxorubicin—thyroid cancer	0.000297	0.000498	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000296	0.000496	CcSEcCtD
Duloxetine—Discomfort—Doxorubicin—thyroid cancer	0.000295	0.000494	CcSEcCtD
Duloxetine—Anorexia—Epirubicin—thyroid cancer	0.000294	0.000493	CcSEcCtD
Duloxetine—NPY1R—GPCR downstream signaling—CALCA—thyroid cancer	0.000292	0.00452	CbGpPWpGaD
Duloxetine—Dry mouth—Doxorubicin—thyroid cancer	0.000292	0.000489	CcSEcCtD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—SST—thyroid cancer	0.00029	0.00449	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000289	0.00448	CbGpPWpGaD
Duloxetine—Confusional state—Doxorubicin—thyroid cancer	0.000288	0.000483	CcSEcCtD
Duloxetine—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000286	0.000479	CcSEcCtD
Duloxetine—Oedema—Doxorubicin—thyroid cancer	0.000286	0.000479	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—TCF7L1—thyroid cancer	0.000286	0.00443	CbGpPWpGaD
Duloxetine—Infection—Doxorubicin—thyroid cancer	0.000284	0.000476	CcSEcCtD
Duloxetine—HTR6—Signaling by GPCR—CALCB—thyroid cancer	0.000282	0.00437	CbGpPWpGaD
Duloxetine—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000281	0.000472	CcSEcCtD
Duloxetine—Shock—Doxorubicin—thyroid cancer	0.000281	0.000471	CcSEcCtD
Duloxetine—Nervous system disorder—Doxorubicin—thyroid cancer	0.00028	0.00047	CcSEcCtD
Duloxetine—Thrombocytopenia—Doxorubicin—thyroid cancer	0.00028	0.000469	CcSEcCtD
Duloxetine—Insomnia—Epirubicin—thyroid cancer	0.000279	0.000468	CcSEcCtD
Duloxetine—Tachycardia—Doxorubicin—thyroid cancer	0.000279	0.000467	CcSEcCtD
Duloxetine—NPY1R—thyroid gland—thyroid cancer	0.000279	0.131	CbGeAlD
Duloxetine—Skin disorder—Doxorubicin—thyroid cancer	0.000278	0.000465	CcSEcCtD
Duloxetine—Paraesthesia—Epirubicin—thyroid cancer	0.000277	0.000465	CcSEcCtD
Duloxetine—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000276	0.000463	CcSEcCtD
Duloxetine—NPY1R—Signaling by GPCR—SST—thyroid cancer	0.000275	0.00427	CbGpPWpGaD
Duloxetine—Somnolence—Epirubicin—thyroid cancer	0.000275	0.00046	CcSEcCtD
Duloxetine—Anorexia—Doxorubicin—thyroid cancer	0.000272	0.000457	CcSEcCtD
Duloxetine—Dyspepsia—Epirubicin—thyroid cancer	0.000272	0.000456	CcSEcCtD
Duloxetine—SLC6A3—NRF2 pathway—NRG1—thyroid cancer	0.000271	0.00419	CbGpPWpGaD
Duloxetine—Decreased appetite—Epirubicin—thyroid cancer	0.000268	0.00045	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000267	0.000447	CcSEcCtD
Duloxetine—Fatigue—Epirubicin—thyroid cancer	0.000266	0.000446	CcSEcCtD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000265	0.00411	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—CALCA—thyroid cancer	0.000265	0.00411	CbGpPWpGaD
Duloxetine—Constipation—Epirubicin—thyroid cancer	0.000264	0.000443	CcSEcCtD
Duloxetine—Pain—Epirubicin—thyroid cancer	0.000264	0.000443	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.00026	0.000436	CcSEcCtD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.00026	0.00403	CbGpPWpGaD
Duloxetine—Insomnia—Doxorubicin—thyroid cancer	0.000258	0.000433	CcSEcCtD
Duloxetine—Paraesthesia—Doxorubicin—thyroid cancer	0.000257	0.00043	CcSEcCtD
Duloxetine—Feeling abnormal—Epirubicin—thyroid cancer	0.000255	0.000427	CcSEcCtD
Duloxetine—HTR6—GPCR ligand binding—TSHR—thyroid cancer	0.000254	0.00394	CbGpPWpGaD
Duloxetine—Somnolence—Doxorubicin—thyroid cancer	0.000254	0.000426	CcSEcCtD
Duloxetine—CYP1A2—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000253	0.00392	CbGpPWpGaD
Duloxetine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000253	0.000423	CcSEcCtD
Duloxetine—Dyspepsia—Doxorubicin—thyroid cancer	0.000252	0.000422	CcSEcCtD
Duloxetine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000252	0.0039	CbGpPWpGaD
Duloxetine—Decreased appetite—Doxorubicin—thyroid cancer	0.000248	0.000416	CcSEcCtD
Duloxetine—NPY1R—head—thyroid cancer	0.000247	0.116	CbGeAlD
Duloxetine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000247	0.000413	CcSEcCtD
Duloxetine—Fatigue—Doxorubicin—thyroid cancer	0.000246	0.000413	CcSEcCtD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000246	0.00381	CbGpPWpGaD
Duloxetine—Urticaria—Epirubicin—thyroid cancer	0.000245	0.000411	CcSEcCtD
Duloxetine—Constipation—Doxorubicin—thyroid cancer	0.000244	0.00041	CcSEcCtD
Duloxetine—Pain—Doxorubicin—thyroid cancer	0.000244	0.00041	CcSEcCtD
Duloxetine—Body temperature increased—Epirubicin—thyroid cancer	0.000244	0.000409	CcSEcCtD
Duloxetine—Abdominal pain—Epirubicin—thyroid cancer	0.000244	0.000409	CcSEcCtD
Duloxetine—CYP2D6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000242	0.00375	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—CDK1—thyroid cancer	0.00024	0.00372	CbGpPWpGaD
Duloxetine—Feeling abnormal—Doxorubicin—thyroid cancer	0.000235	0.000395	CcSEcCtD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000235	0.00364	CbGpPWpGaD
Duloxetine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000234	0.000392	CcSEcCtD
Duloxetine—HTR2C—GPCR downstream signaling—CALCB—thyroid cancer	0.000229	0.00354	CbGpPWpGaD
Duloxetine—Hypersensitivity—Epirubicin—thyroid cancer	0.000228	0.000381	CcSEcCtD
Duloxetine—Urticaria—Doxorubicin—thyroid cancer	0.000227	0.00038	CcSEcCtD
Duloxetine—Body temperature increased—Doxorubicin—thyroid cancer	0.000226	0.000379	CcSEcCtD
Duloxetine—Abdominal pain—Doxorubicin—thyroid cancer	0.000226	0.000379	CcSEcCtD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.000225	0.00349	CbGpPWpGaD
Duloxetine—Asthenia—Epirubicin—thyroid cancer	0.000222	0.000371	CcSEcCtD
Duloxetine—Pruritus—Epirubicin—thyroid cancer	0.000219	0.000366	CcSEcCtD
Duloxetine—HTR6—GPCR ligand binding—PTCH1—thyroid cancer	0.000216	0.00335	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000214	0.00331	CbGpPWpGaD
Duloxetine—Diarrhoea—Epirubicin—thyroid cancer	0.000211	0.000354	CcSEcCtD
Duloxetine—Hypersensitivity—Doxorubicin—thyroid cancer	0.000211	0.000353	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—TSHR—thyroid cancer	0.000209	0.00324	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CALCB—thyroid cancer	0.000208	0.00322	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PRKAR1A—thyroid cancer	0.000206	0.00319	CbGpPWpGaD
Duloxetine—Asthenia—Doxorubicin—thyroid cancer	0.000205	0.000344	CcSEcCtD
Duloxetine—CYP1A2—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000205	0.00318	CbGpPWpGaD
Duloxetine—Dizziness—Epirubicin—thyroid cancer	0.000204	0.000342	CcSEcCtD
Duloxetine—Pruritus—Doxorubicin—thyroid cancer	0.000202	0.000339	CcSEcCtD
Duloxetine—SLC6A4—Circadian rythm related genes—PPARG—thyroid cancer	0.000201	0.00311	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CALCB—thyroid cancer	0.000198	0.00308	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—SST—thyroid cancer	0.000198	0.00307	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MEN1—thyroid cancer	0.000196	0.00305	CbGpPWpGaD
Duloxetine—Vomiting—Epirubicin—thyroid cancer	0.000196	0.000329	CcSEcCtD
Duloxetine—Diarrhoea—Doxorubicin—thyroid cancer	0.000196	0.000328	CcSEcCtD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.000195	0.00303	CbGpPWpGaD
Duloxetine—Rash—Epirubicin—thyroid cancer	0.000195	0.000326	CcSEcCtD
Duloxetine—Dermatitis—Epirubicin—thyroid cancer	0.000195	0.000326	CcSEcCtD
Duloxetine—Headache—Epirubicin—thyroid cancer	0.000193	0.000324	CcSEcCtD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000191	0.00296	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—CALCA—thyroid cancer	0.00019	0.00295	CbGpPWpGaD
Duloxetine—Dizziness—Doxorubicin—thyroid cancer	0.000189	0.000317	CcSEcCtD
Duloxetine—HTR2C—GPCR ligand binding—TSHR—thyroid cancer	0.000187	0.0029	CbGpPWpGaD
Duloxetine—Nausea—Epirubicin—thyroid cancer	0.000183	0.000307	CcSEcCtD
Duloxetine—Vomiting—Doxorubicin—thyroid cancer	0.000182	0.000305	CcSEcCtD
Duloxetine—HTR2A—Signaling by GPCR—CALCB—thyroid cancer	0.00018	0.00279	CbGpPWpGaD
Duloxetine—Rash—Doxorubicin—thyroid cancer	0.00018	0.000302	CcSEcCtD
Duloxetine—Dermatitis—Doxorubicin—thyroid cancer	0.00018	0.000302	CcSEcCtD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—TPR—thyroid cancer	0.00018	0.00279	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—CP—thyroid cancer	0.00018	0.00279	CbGpPWpGaD
Duloxetine—Headache—Doxorubicin—thyroid cancer	0.000179	0.0003	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—PTCH1—thyroid cancer	0.000178	0.00275	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000177	0.00274	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000174	0.0027	CbGpPWpGaD
Duloxetine—HTR6—head—thyroid cancer	0.000174	0.0816	CbGeAlD
Duloxetine—NPY1R—lymph node—thyroid cancer	0.000173	0.0811	CbGeAlD
Duloxetine—Nausea—Doxorubicin—thyroid cancer	0.00017	0.000284	CcSEcCtD
Duloxetine—HTR6—Signaling Pathways—CALCB—thyroid cancer	0.000167	0.00258	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000166	0.00257	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—TSHR—thyroid cancer	0.000163	0.00252	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SST—thyroid cancer	0.000163	0.00252	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000159	0.00247	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—CP—thyroid cancer	0.000159	0.00247	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—PTCH1—thyroid cancer	0.000159	0.00247	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TRIM33—thyroid cancer	0.000158	0.00245	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000157	0.00243	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CALCA—thyroid cancer	0.000156	0.00243	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.000155	0.00241	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.00015	0.00232	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—SST—thyroid cancer	0.000146	0.00226	CbGpPWpGaD
Duloxetine—CYP1A2—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000145	0.00225	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—TSHR—thyroid cancer	0.000144	0.00223	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CDK1—thyroid cancer	0.000142	0.0022	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CALCA—thyroid cancer	0.00014	0.00217	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—PTCH1—thyroid cancer	0.000138	0.00214	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—PTEN—thyroid cancer	0.000138	0.00214	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000135	0.00209	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—TSHR—thyroid cancer	0.00013	0.00202	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—RXRA—thyroid cancer	0.000129	0.00199	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000128	0.00199	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—SST—thyroid cancer	0.000126	0.00196	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CALCB—thyroid cancer	0.000123	0.0019	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CALCA—thyroid cancer	0.000122	0.00189	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.000121	0.00187	CbGpPWpGaD
Duloxetine—HTR2A—neck—thyroid cancer	0.000119	0.056	CbGeAlD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000119	0.00185	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TRIM33—thyroid cancer	0.000116	0.0018	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000116	0.00179	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—BRAF—thyroid cancer	0.000115	0.00178	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NRG1—thyroid cancer	0.000114	0.00176	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000113	0.00175	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—SST—thyroid cancer	0.000112	0.00173	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PTCH1—thyroid cancer	0.000111	0.00172	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—RXRA—thyroid cancer	0.000109	0.00169	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CALCA—thyroid cancer	0.000108	0.00167	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CALCB—thyroid cancer	0.000106	0.00165	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—TSHR—thyroid cancer	0.000106	0.00164	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TCF7L1—thyroid cancer	0.000105	0.00163	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000104	0.00161	CbGpPWpGaD
Duloxetine—SLC6A3—head—thyroid cancer	0.000104	0.0488	CbGeAlD
Duloxetine—NPY1R—Signaling Pathways—TERT—thyroid cancer	0.000102	0.00158	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—SST—thyroid cancer	0.000101	0.00157	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TRIM33—thyroid cancer	0.000101	0.00156	CbGpPWpGaD
Duloxetine—HTR2C—head—thyroid cancer	0.0001	0.0471	CbGeAlD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.0001	0.00155	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CALCA—thyroid cancer	9.77e-05	0.00151	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HIF1A—thyroid cancer	9.76e-05	0.00151	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—TSHR—thyroid cancer	9.61e-05	0.00149	CbGpPWpGaD
Duloxetine—SLC6A4—head—thyroid cancer	9.53e-05	0.0447	CbGeAlD
Duloxetine—HTR2C—Signaling by GPCR—PRKAR1A—thyroid cancer	9.45e-05	0.00147	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MINPP1—thyroid cancer	9.44e-05	0.00146	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—TP53—thyroid cancer	9.4e-05	0.00146	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—TSHR—thyroid cancer	9.19e-05	0.00142	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	8.84e-05	0.00137	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CDK1—thyroid cancer	8.84e-05	0.00137	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—NRAS—thyroid cancer	8.6e-05	0.00133	CbGpPWpGaD
Duloxetine—SLC6A2—head—thyroid cancer	8.39e-05	0.0393	CbGeAlD
Duloxetine—HTR2A—Signaling by GPCR—TSHR—thyroid cancer	8.35e-05	0.00129	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—SST—thyroid cancer	8.23e-05	0.00128	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PRKAR1A—thyroid cancer	8.21e-05	0.00127	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PTCH1—thyroid cancer	8.17e-05	0.00127	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—BRAF—thyroid cancer	8.08e-05	0.00125	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	8.07e-05	0.00125	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NDUFA13—thyroid cancer	8.03e-05	0.00124	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MINPP1—thyroid cancer	8e-05	0.00124	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CALCA—thyroid cancer	7.92e-05	0.00123	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TCF7L1—thyroid cancer	7.76e-05	0.0012	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TSHR—thyroid cancer	7.71e-05	0.0012	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PRKAR1A—thyroid cancer	7.58e-05	0.00118	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CHST14—thyroid cancer	7.55e-05	0.00117	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—SST—thyroid cancer	7.47e-05	0.00116	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—KRAS—thyroid cancer	7.4e-05	0.00115	CbGpPWpGaD
Duloxetine—CYP1A2—thyroid gland—thyroid cancer	7.27e-05	0.0341	CbGeAlD
Duloxetine—HTR6—Signaling Pathways—MEN1—thyroid cancer	7.25e-05	0.00112	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CALCA—thyroid cancer	7.19e-05	0.00112	CbGpPWpGaD
Duloxetine—HTR2A—trachea—thyroid cancer	7.18e-05	0.0337	CbGeAlD
Duloxetine—HTR2A—GPCR downstream signaling—SST—thyroid cancer	7.15e-05	0.00111	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PTCH1—thyroid cancer	7.1e-05	0.0011	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	7.01e-05	0.00109	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	6.95e-05	0.00108	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CALCA—thyroid cancer	6.88e-05	0.00107	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—HRAS—thyroid cancer	6.88e-05	0.00107	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NDUFA13—thyroid cancer	6.8e-05	0.00105	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TCF7L1—thyroid cancer	6.74e-05	0.00104	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTCH1—thyroid cancer	6.55e-05	0.00102	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CDK1—thyroid cancer	6.51e-05	0.00101	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—SST—thyroid cancer	6.49e-05	0.00101	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CHST14—thyroid cancer	6.4e-05	0.000992	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—HRAS—thyroid cancer	6.29e-05	0.000975	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CALCA—thyroid cancer	6.25e-05	0.000968	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—AKT1—thyroid cancer	6.12e-05	0.000948	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HPGD—thyroid cancer	6.09e-05	0.000943	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	6.03e-05	0.000935	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SST—thyroid cancer	6e-05	0.000929	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	5.91e-05	0.000916	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CCND1—thyroid cancer	5.9e-05	0.000914	CbGpPWpGaD
Duloxetine—SLC6A2—lymph node—thyroid cancer	5.87e-05	0.0275	CbGeAlD
Duloxetine—HTR6—Signaling Pathways—CALCA—thyroid cancer	5.77e-05	0.000895	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PTEN—thyroid cancer	5.69e-05	0.000883	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TSHR—thyroid cancer	5.68e-05	0.00088	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CDK1—thyroid cancer	5.65e-05	0.000877	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PRKAR1A—thyroid cancer	5.59e-05	0.000866	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—AKT1—thyroid cancer	5.55e-05	0.000861	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MEN1—thyroid cancer	5.34e-05	0.000827	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—HRAS—thyroid cancer	5.27e-05	0.000817	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CDK1—thyroid cancer	5.22e-05	0.00081	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HPGD—thyroid cancer	5.16e-05	0.000799	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	5.13e-05	0.000795	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NRAS—thyroid cancer	5.08e-05	0.000787	CbGpPWpGaD
Duloxetine—HTR2A—head—thyroid cancer	5.04e-05	0.0236	CbGeAlD
Duloxetine—HTR2A—Signaling Pathways—TSHR—thyroid cancer	4.93e-05	0.000764	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PRKAR1A—thyroid cancer	4.85e-05	0.000752	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTCH1—thyroid cancer	4.83e-05	0.000748	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MEN1—thyroid cancer	4.63e-05	0.000719	CbGpPWpGaD
Duloxetine—CYP2D6—head—thyroid cancer	4.59e-05	0.0215	CbGeAlD
Duloxetine—HTR2C—Signaling Pathways—SST—thyroid cancer	4.41e-05	0.000684	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—KRAS—thyroid cancer	4.37e-05	0.000678	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CALCA—thyroid cancer	4.25e-05	0.000659	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NRG1—thyroid cancer	4.19e-05	0.00065	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTCH1—thyroid cancer	4.19e-05	0.00065	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.18e-05	0.000648	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TP53—thyroid cancer	3.89e-05	0.000602	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDK1—thyroid cancer	3.85e-05	0.000596	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SST—thyroid cancer	3.83e-05	0.000594	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TERT—thyroid cancer	3.76e-05	0.000584	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HRAS—thyroid cancer	3.72e-05	0.000576	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CALCA—thyroid cancer	3.69e-05	0.000572	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HIF1A—thyroid cancer	3.6e-05	0.000558	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TPR—thyroid cancer	3.5e-05	0.000542	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	3.44e-05	0.000533	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDK1—thyroid cancer	3.34e-05	0.000518	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—AKT1—thyroid cancer	3.28e-05	0.000509	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—NRAS—thyroid cancer	3.17e-05	0.000492	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NRG1—thyroid cancer	3.09e-05	0.000479	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—BRAF—thyroid cancer	2.98e-05	0.000462	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TPR—thyroid cancer	2.96e-05	0.000459	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	2.91e-05	0.000452	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TERT—thyroid cancer	2.77e-05	0.00043	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—KRAS—thyroid cancer	2.73e-05	0.000423	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NRG1—thyroid cancer	2.68e-05	0.000416	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HIF1A—thyroid cancer	2.65e-05	0.000411	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.64e-05	0.000409	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC5A5—thyroid cancer	2.62e-05	0.000406	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TERT—thyroid cancer	2.41e-05	0.000373	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—NRAS—thyroid cancer	2.34e-05	0.000362	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HRAS—thyroid cancer	2.32e-05	0.00036	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HIF1A—thyroid cancer	2.3e-05	0.000357	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AKT1—thyroid cancer	2.26e-05	0.00035	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC5A5—thyroid cancer	2.22e-05	0.000344	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—RXRA—thyroid cancer	2.2e-05	0.000341	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—BRAF—thyroid cancer	2.2e-05	0.00034	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCND1—thyroid cancer	2.18e-05	0.000337	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTEN—thyroid cancer	2.1e-05	0.000326	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.08e-05	0.000322	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AKT1—thyroid cancer	2.05e-05	0.000318	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—NRAS—thyroid cancer	2.03e-05	0.000314	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—KRAS—thyroid cancer	2.01e-05	0.000312	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—BRAF—thyroid cancer	1.91e-05	0.000296	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NRAS—thyroid cancer	1.87e-05	0.00029	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—RXRA—thyroid cancer	1.86e-05	0.000289	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.81e-05	0.000281	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—KRAS—thyroid cancer	1.75e-05	0.000271	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HRAS—thyroid cancer	1.71e-05	0.000265	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AKT1—thyroid cancer	1.66e-05	0.000258	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KRAS—thyroid cancer	1.61e-05	0.00025	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCND1—thyroid cancer	1.6e-05	0.000248	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTEN—thyroid cancer	1.55e-05	0.00024	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AKT1—thyroid cancer	1.51e-05	0.000234	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—HRAS—thyroid cancer	1.48e-05	0.00023	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AKT1—thyroid cancer	1.44e-05	0.000224	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—thyroid cancer	1.43e-05	0.000222	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCND1—thyroid cancer	1.39e-05	0.000216	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARG—thyroid cancer	1.39e-05	0.000215	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NRAS—thyroid cancer	1.38e-05	0.000214	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HRAS—thyroid cancer	1.37e-05	0.000213	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTEN—thyroid cancer	1.34e-05	0.000208	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AKT1—thyroid cancer	1.31e-05	0.000203	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKT1—thyroid cancer	1.21e-05	0.000188	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NRAS—thyroid cancer	1.2e-05	0.000186	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KRAS—thyroid cancer	1.19e-05	0.000184	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARG—thyroid cancer	1.18e-05	0.000182	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS2—thyroid cancer	1.09e-05	0.000169	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—thyroid cancer	1.06e-05	0.000164	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KRAS—thyroid cancer	1.03e-05	0.00016	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HRAS—thyroid cancer	1.01e-05	0.000157	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTEN—thyroid cancer	9.52e-06	0.000148	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS2—thyroid cancer	9.25e-06	0.000143	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—thyroid cancer	9.17e-06	0.000142	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT1—thyroid cancer	8.91e-06	0.000138	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HRAS—thyroid cancer	8.77e-06	0.000136	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTEN—thyroid cancer	8.07e-06	0.000125	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT1—thyroid cancer	7.74e-06	0.00012	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKT1—thyroid cancer	5.49e-06	8.51e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKT1—thyroid cancer	4.65e-06	7.21e-05	CbGpPWpGaD
